WallStSmart

Electromed Inc (ELMD)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 49354% more annual revenue ($35.48B vs $71.75M). ELMD leads profitability with a 14.1% profit margin vs 13.0%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 66/100 (B-).

ELMD

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 7.5Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 5.57

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELMDSignificantly Overvalued (-63.4%)

Margin of Safety

-63.4%

Fair Value

$15.46

Current Price

$37.69

$22.23 premium

UndervaluedFair: $15.46Overvalued
MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELMD6 strengths · Avg: 9.2/10
PEG RatioValuation
0.3510/10

Growing faster than its price suggests

EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Altman Z-ScoreHealth
5.5710/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.6%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

Revenue GrowthGrowth
18.4%8/10

18.4% revenue growth

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

ELMD2 concerns · Avg: 3.5/10
P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

Market CapQuality
$312.08M3/10

Smaller company, higher risk/reward

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ELMD

The strongest argument for ELMD centers on PEG Ratio, EPS Growth, Altman Z-Score. Revenue growth of 18.4% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ELMD

The primary concerns for ELMD are P/E Ratio, Market Cap.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ELMD profiles as a growth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.63 — expect wider price swings.

ELMD is growing revenue faster at 18.4% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ELMD scores higher overall (66/100 vs 61/100) and 18.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Electromed Inc

HEALTHCARE · MEDICAL DEVICES · USA

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?